Tempus AI Inc. reported second-quarter 2025 revenue of $314.6 million, topping analysts’ average estimate of about $297 million and marking an 89 percent increase from a year earlier. Adjusted earnings came in at a loss of 22 cents a share, narrower than the 24-cent loss Wall Street had projected, while gross profit jumped 158 percent to $195 million. The diagnostics company processed 212,000 next-generation sequencing tests during the quarter. Adjusted EBITDA improved to a loss of $5.6 million, and the Chicago-based firm now expects to turn a modest $5 million profit on that basis for the full year. Management lifted its 2025 sales outlook to roughly $1.26 billion, citing demand for its AI-driven oncology platform and the impact of a recently announced $200 million collaboration with AstraZeneca. The stronger-than-expected results and higher guidance sent Tempus AI shares up about 12 percent in early U.S. trading.